Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Trifluridine - Tipiracil

Trifluridine - Tipiracil

Trifluridin/Tipiracil (Lonsurf®), which received FDA approval on 22 September 2015, is administered to patients who previously used fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy drugs and drugs preventing new blood vessel formation, with disease spread to distant tissues (metastatic), and colorectal cancer (large bowel cancer) . Lonsurf contains two separate molecules together and can thus be more effective. New blood vessels need to form both for the cancer cell to obtain more nourishment and for it to spread to distant tissues.

Tipiracil inhibits the functioning of thymidine phosphorylase, involved in new blood vessel formation, while Trifluridin binds directly to the cancer cell’s DNA and prevents cell division. Anemia, fatigue, nausea, loss of appetite and decreased blood cells are its most common side effects.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Trifluridine - Tipiracil

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy